Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Common Equity (2016 - 2025)

Historic Common Equity for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $607.2 million.

  • Tg Therapeutics' Common Equity rose 21600.1% to $607.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $607.2 million, marking a year-over-year increase of 21600.1%. This contributed to the annual value of $222.4 million for FY2024, which is 3854.28% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Common Equity is $607.2 million, which was up 21600.1% from $276.4 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Common Equity ranged from a high of $607.2 million in Q3 2025 and a low of $27.4 million during Q1 2023
  • For the 5-year period, Tg Therapeutics' Common Equity averaged around $215.9 million, with its median value being $177.6 million (2024).
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 3301093.87% in 2021, then plummeted by 8389.95% in 2023.
  • Over the past 5 years, Tg Therapeutics' Common Equity (Quarter) stood at $237.2 million in 2021, then tumbled by 75.3% to $58.6 million in 2022, then surged by 173.95% to $160.5 million in 2023, then soared by 38.54% to $222.4 million in 2024, then surged by 173.07% to $607.2 million in 2025.
  • Its Common Equity stands at $607.2 million for Q3 2025, versus $276.4 million for Q2 2025 and $237.3 million for Q1 2025.